Abstract
We investigated the intraocular pressure (IOP) lowering efficacy of preservative-free fixed and non-fixed combination of tafluprost 0.0015% and timolol 0.5% in pseudoexfoliative glaucoma (XFG). A per protocol worse eye analysis was made on all XFG patients who participated in a recent 6 month, prospective, randomized, double-masked, parallel group, multicenter phase III study. The mean time-wise IOP decreased by 8.62 to 10.25 mmHg (31.8 to 36.7%) in the fixed dose combination arm (15 patients) and by 5.38 to 11.35 mmHg (21.3 to 41.2%) in the non-fixed combination arm (13 patients), respectively (p < 0.001 for all comparisons). The results show that a preservative-free fixed dose combination of tafluprost and timolol provides a clinically significant IOP reduction in XFG, and may offer an advantage for the XFG patients with dry eye, due to its preservative-free nature.
Transparency
Declaration of funding
This study was sponsored by Santen Oy, Tampere, Finland. The sponsor participated in the design of the study, conducting the study, data collection, data management, data analysis, data interpretation and the preparation, review and approval of the manuscript.
Declaration of financial/other relationships
G.H. has disclosed that he is a consultant to Santen Oy. A.R. has disclosed that he is an employee of Santen Oy.
CMRO peer reviewers on this manuscript have received an honorarium from CMRO for their review work. Reviewer 1 is an Editorial Board member of CMRO, but has no relevant financial or other relationships to disclose. Reviewer 2 has no relevant financial or other relationships to disclose.